Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

rthritis. ChemoCentryx is privately held. For more information, please refer to http://www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (viii) the timing or likelihood of regulatory filings and approvals, (ix) the availability of corporate partners, (x)
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Today, Rhodes ... nervous system stimulant indicated for the treatment of ... beginning Summer 2015. The announcement ... approval from the U.S. Food and Drug Administration ... extended-release formulation of methylphenidate capsule with an onset ...
(Date:5/22/2015)... REDWOOD CITY, Calif. , May 22, 2015 /PRNewswire/ ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today announced that interim chief executive officer ... 2015 Healthcare Conference and chief financial officer Tim ... Science Conference. Details of the two presentations are as ...
(Date:5/21/2015)... 2015  When Ryan Rendino first felt ... his neck, he figured it was a ... off from weight lifting. But ... A series of doctor appointments ... Michel Kliot, MD , a ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... 24, 2012   Sanovas , a leading developer ... cancer and chronic diseases, announced today that it ... manufacturing site in Sausalito, Calif. The facility will ... of filing for U.S. Food and Drug Administration ...
... Medical Inc. (OTCBB:ONCS), which is developing its ... therapies to treat solid tumor cancers, today announced ... OncoSec, will be presenting at the World Cancer ... (Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO ) ...
Cached Medicine Technology:Sanovas Expands Headquarters and Opens Manufacturing Site 2OncoSec to Present at World Cancer Immunotherapy Conference 2OncoSec to Present at World Cancer Immunotherapy Conference 3
(Date:5/24/2015)... (PRWEB) May 24, 2015 Women's ... about hair loss. Although it is unclear about the ... are environmental factors such as metabolism, nutritional deficiencies, thyroid ... they offer a comprehensive approach to evaluating the metabolic, ... woman, they can help patients find a cause for ...
(Date:5/24/2015)... May 24, 2015 Scientists with Cardno ... on air quality compliance issues that may have raised ... Surviving Mesothelioma has just posted an article on the ... , The group found airborne asbestos levels well above ... between 1984 and 2011. , “Asbestos compliance sampling data ...
(Date:5/24/2015)... ProPin is a set of self-animating 3D pin ... ProPin to pin point locations on a map, to indicate prices ... allows users to choose from 30 simplistic presets with geometric design ... video editors can easily manipulate ProPin presets as a whole. ... ease. , Using ProPin is easy, simply drag a preset into ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... 23, 2015 On May 13, Nithyananda ... a youngster's yogic power learned through meditation and initiation ... in Bangalore, India. , Yogamaatha, a nine-year-old girl from ... high profile professionals attending the 2015 Business Advocacy Summit ... -- blindfolded. , In a demonstration that lasted ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... Ceylan, from Turkey evaluated their experience in 48 cases ... ages ranged from 5 months to 24 years with ... performed at various centers or during religious ceremonies in ... found that the most commonly observed complication was preputio-glandular ...
... toxic chemicals and industrial effluents in sea and soil could increase ... obesity was thought to be the most important factor in the ... body does not produce enough insulin - necessary for the body ... by South Korean researchers has shown that people whose bodies are ...
... casts a shadow the length of a lifetime.” , - Herbert ... Sana was home alone, happy in her imaginative world of fairies ... neighborhood household. A knock on the door jolted her out of ... man, her uncle, was a devil in disguise. He locked the ...
... men, the erectile-dysfunction drugs Viagra, Cialis, and Levitra are ... in Midlife and Beyond,// a new report from Harvard ... the emotional and relationship pressures that frequently accompany erectile ... work only if the man is feeling sexual desire ...
... Australia’s already pressured hospital system would struggle to cope ... of a large-scale emergency, say trauma and emergency specialists.// ... preparedness targets for Australasian hospitals, says Dr Anthony Joseph, ... ,In the latest Medical Journal of ...
... A study conducted recently has shown that students who ... tendencies // like those who did not participate in ... not create the desired positive impact. ... being spent by the Federal government annually on the ...
Cached Medicine News:Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 3Health News:Can Our Hospitals Cope In A Disaster? 2
... the way for faster, easier, and more ... utilizes the latest digital FireWire technology, allowing ... images. Its ease of use allows technicians ... extraordinary time reduction frees technicians to perform ...
... The ADVIA 1200 system features a small footprint, which ... , , Standardization as Part of the ADVIA ... same reagents, calibrators and controls as the other members ... the same proven reliability. , , Meets Workload ...
... The Stryker Wedge Suture Anchors are ... sizes and styles. The Wedge anchors are ... surgeon and OR staff. The following sizes ... 1 Suture, 5.0mm Single Eyelet 2 Sutures, ...
RCB™ Rotator Cuff Buttress is a completely resorbable plate that will alleviate suture migration in open or mini-Open rotator cuff repairs....
Medicine Products: